10/657,812

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1129pxo

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4	AUG 11	STN AnaVist workshops to be held in North America
NEWS 5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS 6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8	OCT 03	MATHDI removed from STN
NEWS 9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10	OCT 06	STN AnaVist workshops to be held in North America
NEWS 11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 13	OCT 27	Free KWIC format extended in full-text databases
NEWS 14	OCT 27	DIOGENES content streamlined
NEWS 15	OCT 27	EPFULL enhanced with additional content

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:34:29 ON 13 NOV 2005

```
=> d his

     (FILE 'HOME' ENTERED AT 18:34:29 ON 13 NOV 2005)

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.10       2.10

FILE 'REGISTRY' ENTERED AT 18:40:26 ON 13 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 NOV 2005  HIGHEST RN 867335-63-5
DICTIONARY FILE UPDATES:  11 NOV 2005  HIGHEST RN 867335-63-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html
```

=>
Uploading C:\Program Files\Stnexp\Queries\10657812b.str

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10657812c.str

L2 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR





G1 CF2,CCl2,CBr2,SO2,CN,NO2,[@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 18:41:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               0 TO        0

L3             0 SEA SSS SAM L1

=> s l2
SAMPLE SEARCH INITIATED 18:41:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       27 TO ITERATE

100.0% PROCESSED       27 ITERATIONS                                8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          229 TO      851
PROJECTED ANSWERS:               8 TO      329

L4             8 SEA SSS SAM L2

=> search l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 18:41:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       87 TO ITERATE

100.0% PROCESSED       87 ITERATIONS                               12 ANSWERS
SEARCH TIME: 00.00.01

L5            12 SEA SSS FUL L1

=> search l2
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 18:41:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      475 TO ITERATE

100.0% PROCESSED      475 ITERATIONS                              144 ANSWERS
SEARCH TIME: 00.00.01

L6           144 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             322.66     324.76
```

FILE 'CAPLUS' ENTERED AT 18:41:31 ON 13 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Nov 2005 VOL 143 ISS 21
FILE LAST UPDATED: 11 Nov 2005 (20051111/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5 or l6
8 L5
5 L6
L7 9 L5 OR L6

=> d l7 fbib ab hitstr 1-9

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220311 CAPLUS
DN 140:271195
TI Preparation of N'-arylaminocarbothioyl glycinamides as glycine transport inhibitors for treating pain and spasticity
IN Isaac, Methvin; Xin, Tao; Stefanac, Tomaslav; O'Brien, Anne; Da Silva, Kathleen; Arora, Jalaj; Maddaford, Shawn; Slassi, Abdelmalik
PA Nps Allelix Corp., Can.
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022534	A1	20040318	WO 2003-CA1370	20030909

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2002-409420P	P 20020909

US 2004152740 A1 20040805 US 2003-657812 20030908
US 2002-409420P P 20020909

OS MARPAT 140:271195

AB The present invention relates to R1NHC(O)CR2R3NHC(S)NHAr1 (I; e.g. N-(2,6-dimethylphenyl)-2-[3-[4-(dimethylsulfamoyl)-2-nitrophenyl]thioureido]-2-phenylacetamide (II)) and salts, solvates and hydrates thereof. The invention further relates to pharmaceutical compns. containing said compds. and methods of treating neurol. and neuropsychiatric disorders using said compds. IC50 values for 15 examples of I for inhibiting the GlyT-2 glycine transporter are tabulated, e.g. 14.22 nM for II. Although the methods of preparation are not claimed, many example prepns. are included. For example, II was prepared in 94% yield from 2-amino-N-(2,6-dimethylphenyl)-2-phenylacetamide and 2-nitro-4-(dimethylsulfamoyl)phenyl isothiocyanate. For I: R1 = aryl, heteroaryl, cycloalkyl and heterocycloalkyl; wherein R1 is (un)substituted with ≥1 substituents Ra; wherein Ra = alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, aryl, heteroaryl, aralkyl, heteroaralkyl and -(R7)nNR8R9 (R7 = alkyl, alkoxy, and oxyalkyl, R8 and R9 = H, and alkyl, or R8 and R9 can join together such that NR8R9 form a 5 or 6-member heterocyclic ring, and n = 0-3) wherein the substituent(s) Ra is optionally further substituted with ≥1 substituents = alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, and -(R7)nNR8R9. R2 and R3 are: (a) independently H, alkyl, aralkyl (un)substituted aryl, (un)substituted heteroaryl and (un)substituted, (un)saturated, 5- or 6-membered, homocyclic or heterocyclic rings wherein the optional substituent may be H, alkyl, alkoxy, and halo; or (b) joined together to form a 3-7 member spirocyclic ring. Ar1 is aryl and is (un)substituted with ≥1 substituents Rb = alkyl, alkoxy, halo, haloalkyl, nitro, -(R7)nNR8R9, alkanoyl, aryl, heteroaryl, -O(CH2)mNR10R11 and -SO2NR10R11 (R7 = alkyl, alkoxy and oxyalkyl; R8 and R9 = H, and alkyl, or R8 and R9 can join together such that NR8R9 form a 5 or 6-member heterocyclic ring, and n = 0-3) and the groups R10 and R11 = H, or alkyl, or groups R10 and R11 can join together such that NR10R11 form a 5 or 6-member ring, and m = 1-5; Rb are optionally further substituted. When Ar1 is Ph then (a) Ar1 has a substituent Rb at the 2-position wherein the substituent = nitro, haloalkyl, cyano, - C(O)R12 -C(O)OR12, -C(O)NR12R12, -S(O)R12, -S(O)2R12, and -S(O)2NR12R13 (wherein R12 and R13 = H and alkyl) or (b) Ar1 has an alkanoyl substituent at the 4-position.

IT **672961-09-0P**, N-(2,6-Dimethylphenyl)-2-[3-[4-[2-(N,N-dimethylamino)ethoxy]-2-nitrophenyl]thioureido]-2-phenylacetamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N'-arylaminocarbothioyl glycinamides as glycine transport inhibitors for treating pain and spasticity)

RN 672961-09-0 CAPLUS

CN Benzeneacetamide, α-[[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **672959-44-3P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-methylacetamide **672959-52-3P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-isopropylacetamide **672959-57-8P**, (R)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-isopropylacetamide **672959-62-5P**, (S)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-isopropylacetamide **672959-67-0P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672959-68-1P**, N-(2-Methylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672959-69-2P**, N-(2-Methylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide **672959-70-5P**, N-(2-Methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672959-72-7P**, N-(2-Methylphenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672959-73-8P**, N-(2-Methylphenyl)-2-[3-[4-(2-N,N-dimethylaminoethoxy)-2-nitrophenyl]thioureido]-2-phenylacetamide **672959-79-4P**, (R)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672959-80-7P**, (R)-N-(2-Methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672959-97-6P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-benzylacetamide **672960-01-9P** **672960-16-6P**, (S)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-cyclohexylacetamide **672960-18-8P**, (R)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-cyclohexylacetamide **672960-24-6P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-(2-methylpropyl)acetamide **672960-33-7P**, N-(2-Methoxycarbonylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-34-8P**, N-(2-Methoxycarbonylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide **672960-35-9P**, N-(2-Methoxycarbonylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-38-2P**, N-(2-Cyanophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-41-7P**, N-(2-Methoxyphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-42-8P**, N-(2-Methoxyphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide **672960-43-9P**, N-(2-Methoxyphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-46-2P**, N-(2-Methylthiophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-47-3P**, N-(2-Methylthiophenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide **672960-48-4P**, N-(2-Methylthiophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-51-9P**, N-(2-Chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-52-0P**, N-(2-Chlorophenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-53-1P**, N-(2-Chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-56-4P**, N-(3-Chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-57-5P**, N-(3-Chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-58-6P**, N-(3-Chlorophenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-61-1P**, N-(4-Chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-62-2P**, N-(4-Chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-63-3P**, N-(4-Chlorophenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-66-6P**, N-(2,3-Dimethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-67-7P**, N-(2,3-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-70-2P**, N-(5,6,7,8-Tetrahydronaphthalen-1-yl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-71-3P**

, N-(5,6,7,8-Tetrahydronaphthalen-1-yl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-74-6P**, N-(2-Methyl-4-chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-75-7P**, N-(2-Methyl-4-chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-78-0P**, N-(5-Phenyl-2-methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-79-1P**, N-(5-Phenyl-2-methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-82-6P**, N-(4-Phenyl-2-methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-83-7P**, N-(4-Phenyl-2-methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-85-9P**, N-(6-Ethyl-2-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-88-2P**, N-(2-Isopropyl-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-91-7P**, N-(2-Chloro-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-94-0P**, N-(2,4-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-97-3P**, N-(2,5-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-00-1P**, N-(2-Methyl-1-naphthyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-02-3P**, N-(2,6-Dimethylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-03-4P**, N-(2,6-Dimethylphenyl)-2-[3-[2-[(N,N-dimethylamino)sulfonyl]phenyl]thioureido]-2-phenylacetamide **672961-05-6P**, N-(2,6-Dimethylphenyl)-2-[3-(2-N-methylpiperazin-1-ylsulfonylphenyl)thioureido]-2-phenylacetamide **672961-10-3P**, N-(2,6-Dimethylphenyl)-2-[3-[2-nitro-4-[2-(N,N-dimethylamino)ethoxy]phenyl]thioureido]-2-phenylacetamide hydrochloride **672961-12-5P**, N-(2,6-Dimethylphenyl)-2-[3-[4-[(N,N-dimethylamino)sulfonyl]-2-nitrophenyl]thioureido]-2-phenylacetamide **672961-13-6P**, N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-14-7P**, N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672961-17-0P**, N-(2,6-Dimethylphenyl)-2-[3-[4-(2-N,N-dimethylaminoethoxy)-2-trifluoromethylphenyl]thioureido]-2-phenylacetamide **672961-21-6P**, N-(2,6-Dimethylphenyl)-2-[3-[4-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-trifluoromethylphenyl]thioureido]-2-phenylacetamide **672961-22-7P**, N-(2,6-Dimethylphenyl)-2-[3-(4-methyl-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-23-8P**, N-(2,6-Dimethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-38-5P**, N-(4-Methylphenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672961-39-6P**, N-(4-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-40-9P**, N-(Phenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-41-0P**, N-(Phenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672961-46-5P**, N-(3-Methylphenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672961-47-6P**, N-(3-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-57-8P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-cyclohexylacetamide **672961-58-9P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-cyclohexylacetamide **672961-59-0P**, N-(2-Isopropylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide **672961-61-4P**, N-(2-Isopropylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-62-5P**, N-(2-Isopropylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672961-63-6P**, N-(2-Phenylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-67-0P**, N-(1-Naphthyl)-2-[3-(2-nitrophenyl)thioureido]-2-

phenylacetamide **672961-68-1P**, N-[2-(4-Methylpiperazin-1-yl)phenyl]-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672961-70-5P**, N-[2-(4-Methylpiperazin-1-yl)phenyl]-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-73-8P**, N-(2-Methylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672961-74-9P**, N-(2-Methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672961-76-1P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672961-81-8P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-(3-trifluoromethylphenyl)acetamide **672961-87-4P**, N-(2-Methylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-2-(3-thienyl)acetamide **672961-88-5P**, N-(2-Methylphenyl)-2-[3-(2-methoxy-5-nitrophenyl)thioureido]-2-(3-thienyl)acetamide **672961-89-6P**, N-(2-Methylphenyl)-2-[3-(3-trifluoromethylphenyl)thioureido]-2-(3-thienyl)acetamide **672961-90-9P**, N-(2-Methylphenyl)-2-[3-(2-Nitrophenyl)thioureido]-2-(3-thienyl)acetamide **672961-93-2P**, N-(2-Trifluoromethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-94-3P**, N-(2-Ethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-99-8P**,. (R)-N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-4-methylpentanamide **672962-00-4P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-4-methylpentanamide **672962-01-5P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-4-methylpentanamide **672962-02-6P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-[4-(2-dimethylaminoethoxy)-2-nitrophenyl]thioureido]-4-methylpentanamide **672962-05-9P**, N-(5-Methoxy-2-methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672962-10-6P**, N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672962-15-1P**, N-(4-Isopropylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672962-17-3P**, N-(4-Nitrophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672962-19-5P**, N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-(3,4-difluorophenyl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N'-arylaminocarbothioyl glycinamides as glycine transport inhibitors for treating pain and spasticity)

RN 672959-44-3 CAPLUS
CN Propanamide, N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672959-52-3 CAPLUS
CN Butanamide, 3-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672959-57-8 CAPLUS
CN Butanamide, 3-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672959-62-5 CAPLUS
CN Butanamide, 3-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672959-67-0 CAPLUS
CN Benzeneacetamide, N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672959-68-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672959-69-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672959-70-5 CAPLUS
CN Benzeneacetamide, N-(2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672959-72-7 CAPLUS
CN Benzeneacetamide, N-(2-methylphenyl)-α-[[(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672959-73-8 CAPLUS
CN Benzeneacetamide, α-[[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672959-79-4 CAPLUS
CN Benzeneacetamide, N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672959-80-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672959-97-6 CAPLUS
CN Benzenepropanamide, N-(2-methylphenyl)-α-[[[(2-

nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-01-9 CAPLUS
CN Propanamide, 2-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-16-6 CAPLUS
CN Cyclohexaneacetamide, N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672960-18-8 CAPLUS
CN Cyclohexaneacetamide, N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672960-24-6 CAPLUS
CN Pentanamide, 4-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-33-7 CAPLUS
CN Benzoic acid, 2-[[[[[(2-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 672960-34-8 CAPLUS
CN Benzoic acid, 2-[[[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 672960-35-9 CAPLUS
CN Benzoic acid, 2-[[phenyl[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 672960-38-2 CAPLUS
CN Benzeneacetamide, N-(2-cyanophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-41-7 CAPLUS
CN Benzeneacetamide, N-(2-methoxyphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-42-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 672960-43-9 CAPLUS
CN Benzeneacetamide, N-(2-methoxyphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-46-2 CAPLUS

CN Benzeneacetamide, N-[2-(methylthio)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-47-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 672960-48-4 CAPLUS
CN Benzeneacetamide, N-[2-(methylthio)phenyl]-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-51-9 CAPLUS
CN Benzeneacetamide, N-(2-chlorophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-52-0 CAPLUS
CN Benzeneacetamide, N-(2-chlorophenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-53-1 CAPLUS
CN Benzeneacetamide, N-(2-chlorophenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-56-4 CAPLUS
CN Benzeneacetamide, N-(3-chlorophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-57-5 CAPLUS
CN Benzeneacetamide, N-(3-chlorophenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-58-6 CAPLUS
CN Benzeneacetamide, N-(3-chlorophenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-61-1 CAPLUS
CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-62-2 CAPLUS
CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-63-3 CAPLUS
CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-66-6 CAPLUS
CN Benzeneacetamide, N-(2,3-dimethylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-67-7 CAPLUS
CN Benzeneacetamide, N-(2,3-dimethylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-70-2 CAPLUS
CN Benzeneacetamide, α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 672960-71-3 CAPLUS
CN Benzeneacetamide, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-74-6 CAPLUS
CN Benzeneacetamide, N-(4-chloro-2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-75-7 CAPLUS
CN Benzeneacetamide, N-(4-chloro-2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-78-0 CAPLUS
CN Benzeneacetamide, N-(4-methyl[1,1'-biphenyl]-3-yl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-79-1 CAPLUS
CN Benzeneacetamide, N-(4-methyl[1,1'-biphenyl]-3-yl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-82-6 CAPLUS
CN Benzeneacetamide, N-(3-methyl[1,1'-biphenyl]-4-yl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-83-7 CAPLUS
CN Benzeneacetamide, N-(3-methyl[1,1'-biphenyl]-4-yl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-85-9 CAPLUS
CN Benzeneacetamide, N-(2-ethyl-6-methylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-88-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-methyl-6-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672960-91-7 CAPLUS
CN Benzeneacetamide, N-(2-chloro-6-methylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-94-0 CAPLUS
CN Benzeneacetamide, N-(2,4-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-97-3 CAPLUS
CN Benzeneacetamide, N-(2,5-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-00-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 672961-02-3 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-03-4 CAPLUS
CN Benzeneacetamide, α-[[[[2-[(dimethylamino)sulfonyl]phenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 672961-05-6 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[[2-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-10-3 CAPLUS
CN Benzeneacetamide, α-[[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 672961-12-5 CAPLUS
CN Benzeneacetamide, α-[[[[4-[(dimethylamino)sulfonyl]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 672961-13-6 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-14-7 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-17-0 CAPLUS
CN Benzeneacetamide, α-[[[[4-[2-(dimethylamino)ethoxy]-2-(trifluoromethyl)phenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 672961-21-6 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[[4-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-2-(trifluoromethyl)phenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-22-7 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[(4-methyl-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-23-8 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-38-5 CAPLUS
CN Benzeneacetamide, N-(4-methylphenyl)-α-[[(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-39-6 CAPLUS
CN Benzeneacetamide, N-(4-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-40-9 CAPLUS
CN Benzeneacetamide, α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 672961-41-0 CAPLUS
CN Benzeneacetamide, α-[[(1-naphthalenylamino)thioxomethyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 672961-46-5 CAPLUS
CN Benzeneacetamide, N-(3-methylphenyl)-α-[[(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-47-6 CAPLUS
CN Benzeneacetamide, N-(3-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-57-8 CAPLUS
CN Cyclohexaneacetamide, N-(2,6-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672961-58-9 CAPLUS
CN Cyclohexaneacetamide, N-(2,6-dimethylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672961-59-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672961-61-4 CAPLUS
CN Benzeneacetamide, N-[2-(1-methylethyl)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-62-5 CAPLUS
CN Benzeneacetamide, N-[2-(1-methylethyl)phenyl]-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-63-6 CAPLUS
CN Benzeneacetamide, N-[1,1'-biphenyl]-2-yl-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-67-0 CAPLUS
CN Benzeneacetamide, N-1-naphthalenyl-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-68-1 CAPLUS
CN Benzeneacetamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-70-5 CAPLUS
CN Benzeneacetamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-73-8 CAPLUS
CN Benzeneacetamide, 3,4-difluoro-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672961-74-9 CAPLUS
CN Benzeneacetamide, 3,4-difluoro-N-(2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-76-1 CAPLUS
CN Benzeneacetamide, 3,4-difluoro-N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-81-8 CAPLUS
CN Benzeneacetamide, N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 672961-87-4 CAPLUS
CN 3-Thiopheneacetamide, α-[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672961-88-5 CAPLUS
CN 3-Thiopheneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672961-89-6 CAPLUS
CN 3-Thiopheneacetamide, N-(2-methylphenyl)-α-[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-90-9 CAPLUS
CN 3-Thiopheneacetamide, N-(2-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-93-2 CAPLUS
CN Benzeneacetamide, α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672961-94-3 CAPLUS
CN Benzeneacetamide, N-(2-ethylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-99-8 CAPLUS
CN Pentanamide, N-(2,6-dimethylphenyl)-4-methyl-2-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672962-00-4 CAPLUS
CN Pentanamide, N-(2,6-dimethylphenyl)-2-[[[(4-methoxy-2-

nitrophenyl)amino]thioxomethyl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672962-01-5 CAPLUS
CN Pentanamide, N-(2,6-dimethylphenyl)-2-[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672962-02-6 CAPLUS
CN Pentanamide, 2-[[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672962-05-9 CAPLUS
CN Benzeneacetamide, N-(5-methoxy-2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-10-6 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-3,4-difluoro-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-15-1 CAPLUS
CN Benzeneacetamide, N-[4-(1-methylethyl)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-17-3 CAPLUS
CN Benzeneacetamide, N-(4-nitrophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-19-5 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-3,4-difluoro-α-[[thioxo[[2-

(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220306 CAPLUS
DN 140:271194
TI Arylglycine derivatives and their use as glycine transport inhibitors
IN Isaac, Methvin; Xin, Tao; Edwards, Louise; Begleiter, Leah; Stefanac, Tomaslav; O'Brien, Anne; Da Silva, Kathleen; Arora, Jalaj; Maddaford, Shawn; Slassi, Abdelmalik
PA Nps Allelix Corp., Can.
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022528	A2	20040318	WO 2003-CA1369	20030909
	WO 2004022528	A3	20040521		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-409421P	P 20020909
	US 2004152741	A1	20040805	US 2003-657815	20030908
				US 2002-409421P	P 20020909

OS MARPAT 140:271194
AB The invention relates to compds. R1NHCOCR2R3NHC(:X)NHAr1 [R1 is (un)substituted (hetero)cycloalkyl or (hetero)aryl; R2, R3 are H, alkyl, haloalkyl, aralkyl, or a group given for R1; X is O, S, NH, or NCN; Ar1 is aryl (with provisos)] and their salts, solvates, and hydrates for treating neurol., neuropsychiatric, and gastrointestinal disorders. Thus, N-(indan-5-yl)-2-[3-(2-methoxy-5-nitrophenyl)thioureido]-2-(3-thienyl)acetamide (claimed compound) was prepared by condensation of (±)-3-thienylglycine indan-5-ylamide (preparation given) with 2-methoxy-5-nitrophenyl isocyanate and showed IC50 = 131.448 nM for

glycine uptake.

IT **672961-38-5P 672962-37-7P 672962-43-5P**
672962-48-0P 672962-52-6P 672962-53-7P
672962-58-2P 672962-59-3P 672962-60-6P
672962-61-7P 672962-62-8P 672962-63-9P
672962-64-0P 672962-67-3P 672962-68-4P
672962-69-5P 672962-80-0P 672962-81-1P
672962-82-2P 672962-85-5P 672962-86-6P
672962-89-9P 672962-94-6P 672962-97-9P
672963-00-7P 672963-04-1P 672963-05-2P
672963-11-0P 672963-15-4P 672963-19-8P
672963-20-1P 672963-27-8P 672963-32-5P
672963-36-9P 672963-37-0P 672963-45-0P
672963-47-2P 672963-48-3P 672963-52-9P
672963-53-0P 672963-61-0P 672963-70-1P
672963-74-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylglycine derivs. as inhibitors of glycine transport in treatment of neurol. and gastrointestinal disorders)

RN 672961-38-5 CAPLUS
CN Benzeneacetamide, N-(4-methylphenyl)-α-[[(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-37-7 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672962-43-5 CAPLUS
CN Benzeneacetamide, N-(2-methylphenyl)-α-[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-48-0 CAPLUS
CN Cyclohexaneacetamide, N-(2-methylphenyl)-α-[[[(3-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-52-6 CAPLUS
CN Benzeneacetamide, N-(3-chlorophenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-53-7 CAPLUS
CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-58-2 CAPLUS
CN Benzeneacetamide, N-(2,3-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-59-3 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 672962-60-6 CAPLUS
CN Benzeneacetamide, N-(4-chloro-2-methylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-61-7 CAPLUS
CN Benzeneacetamide, N-(2-ethyl-6-methylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-62-8 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[2-methyl-6-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-63-9 CAPLUS
CN Benzeneacetamide, N-(2-chloro-6-methylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-64-0 CAPLUS
CN Benzeneacetamide, N-(2,4-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-67-3 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672962-68-4 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672962-69-5 CAPLUS
CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672962-80-0 CAPLUS
CN Benzeneacetamide, 3,4-difluoro-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-81-1 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-3-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-82-2 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-85-5 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-86-6 CAPLUS
CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-89-9 CAPLUS
CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-94-6 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 672962-97-9 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672963-00-7 CAPLUS
CN Benzeneacetamide, N-[3-(dimethylamino)phenyl]-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-04-1 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 672963-05-2 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 672963-11-0 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 672963-15-4 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 672963-19-8 CAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-1H-inden-5-yl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-20-1 CAPLUS
CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)



RN 672963-27-8 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 672963-32-5 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672963-36-9 CAPLUS

CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]am
ino]-N-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 672963-37-0 CAPLUS
CN Benzeneacetamide, N-(3,4-dimethylphenyl)-α-[[[(2-methoxy-5-
nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-45-0 CAPLUS
CN Benzeneacetamide, N-(3,4-dimethylphenyl)-α-[[[(2-methoxy-5-
nitrophenyl)amino]thioxomethyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672963-47-2 CAPLUS
CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]am
ino]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 672963-48-3 CAPLUS
CN Benzeneacetamide, N-(3,5-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-52-9 CAPLUS
CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-ethenylphenyl)- (9CI) (CA INDEX NAME)



RN 672963-53-0 CAPLUS
CN Benzeneacetamide, N-(4-ethenylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-61-0 CAPLUS
CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]a

mino]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 672963-70-1 CAPLUS
CN 3-Thiopheneacetamide, N-(3,4-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-74-5 CAPLUS
CN 3-Thiopheneacetamide, N-(2,3-dihydro-1H-inden-5-yl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



IT **672963-62-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylglycine derivs. as inhibitors of glycine transport in treatment of neurol. and gastrointestinal disorders)

RN 672963-62-1 CAPLUS

CN Benzeneacetamide, N-(4-bromophenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:757692 CAPLUS

DN 139:261159

TI Preparation of cyclic hemiacetal derivative and use thereof

IN Nakamura, Masayuki; Inoue, Jun

PA Senju Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078415	A1	20030925	WO 2003-JP3122	20030314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2002-72762	A 20020315
	EP 1489076	A1	20041222	EP 2003-712708	20030314
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				JP 2002-72762	A 20020315
				WO 2003-JP3122	W 20030314
	US 2005119499	A1	20050602	US 2003-507831	20030314
				JP 2002-72762	A 20020315
				WO 2003-JP3122	W 20030314

OS MARPAT 139:261159

AB The patent relates to the preparation of calpain inhibitor cyclic hemiacetal compound I (R1 = lower alkyl; R2 = H, halo, cyano, lower alkyl, lower alkoxy; n = 0, 1). A title compound I (n = 0, R1 = iCH2CHMe2, R2 = H), prepared by reduction of the corresponding oxo-precursor with

diisobutylaluminium hydride, was formulated in a eye drop composition

IT **602307-54-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic hemiacetal derivative having calpain inhibitive activity)

RN 602307-54-0 CAPLUS

CN Pentanamide, 2-[[[(3-cyanophenyl)amino]thioxomethyl]amino]-4-methyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:789155 CAPLUS

DN 123:199414

TI Preparation of peptidyllactol derivatives as inhibitors of cathepsin L.

IN Sohda, Takashi; Fujisawa, Yukio; Oi, Satoru; Mizoguchi, Junji

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 54 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	EP 641800	A1	19950308	EP 1994-113669		19940901
	EP 641800	B1	20020116			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
				JP 1993-219655	A	19930903
				JP 1994-168501	A	19940720
				JP 1994-190385	A	19940812
	NO 9403210	A	19950306	NO 1994-3210		19940830
				JP 1993-219655	A	19930903
				JP 1994-168501	A	19940720
				JP 1994-190385	A	19940812
	JP 08104685	A2	19960423	JP 1994-208981		19940901
				JP 1993-219655	A	19930903
				JP 1994-168501	A	19940720
				JP 1994-190385	A	19940812
	AT 212036	E	20020215	AT 1994-113669		19940901
				JP 1993-219655	A	19930903
				JP 1994-168501	A	19940720

			JP 1994-190385	A	19940812
CA 2131397	AA	19950304	CA 1994-2131397		19940902
			JP 1993-219655	A	19930903
			JP 1994-168501	A	19940720
			JP 1994-190385	A	19940812
FI 9404040	A	19950304	FI 1994-4040		19940902
			JP 1993-219655	A	19930903
			JP 1994-168501	A	19940720
			JP 1994-190385	A	19940812
AU 9471682	A1	19950316	AU 1994-71682		19940902
AU 678493	B2	19970529			
			JP 1993-219655	A	19930903
			JP 1994-168501	A	19940720
			JP 1994-190385	A	19940812
HU 68717	A2	19950728	HU 1994-2536		19940902
			JP 1993-219655	A	19930903
			JP 1994-168501	A	19940720
			JP 1994-190385	A	19940812
CN 1106001	A	19950802	CN 1994-115669		19940902
			JP 1993-219655	A	19930903
			JP 1994-190385	A	19940812
US 5496834	A	19960305	US 1994-300738		19940902
			JP 1993-219655	A	19930903
			JP 1994-168501	A	19940720
			JP 1994-190385	A	19940812

OS CASREACT 123:199414; MARPAT 123:199414

AB Title compds. [I; Q = 1-2 (substituted) amino acid residues; R3 = (esterified) carboxyl, acyl; A = alkylene; B = H, (substituted) alkyl, acyl], were prepared Thus, N-benzyloxycarbonylhomoserine, 1-hydroxybenzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide were stirred 14 h in DMF at ice temp-room temperature to give 84.3% (S)-3-(N-benzyloxycarbonylamino)tetrahydrofuran-2-one. This was hydrogenolyzed in EtOH over Pd/C and the product was stirred with BOC-Phe-OH, 1-hydroxybenzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in DMF to give 78.3% (S)-3-(N-tert-butoxycarbonylphenylalanylamino)tetrahydrofuran-2-one. The latter in THF was treated with DIBAL in PhMe at -72° to give 37.5% title compound (II). I inhibited cathepsin L with IC50 = 6.9 + 10-7-8.0 + 10-9 M, and at 10-30 μM gave 26-82% inhibition of bone resorption in rat fetuses according to the method of Raisz.

IT **167765-33-5P 167765-34-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidyllactol derivs. as inhibitors of cathepsin L)

RN 167765-33-5 CAPLUS

CN Pentanamide, 4-methyl-2-[[(1-naphthalenylamino)thioxomethyl]amino]-N-(tetrahydro-2-hydroxy-3-furanyl)-, [2R-[2α,3α(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167765-34-6 CAPLUS
CN Pentanamide, 4-methyl-2-[[(1-naphthalenylamino)thioxomethyl]amino]-N-(tetrahydro-2-hydroxy-3-furanyl)-, [2S-[2α,3β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **167766-65-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptidyllactol derivs. as inhibitors of cathepsin L)
RN 167766-65-6 CAPLUS
CN Pentanamide, 4-methyl-2-[[(1-naphthalenylamino)thioxomethyl]amino]-N-(tetrahydro-2-oxo-3-furanyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1984:138858 CAPLUS
DN 100:138858
TI β-Lactam compounds

IN Bognar, Rezsoe; Jaszberanyi, Csaba; Farkas, Erzsebet; Punyiczki, Maria; Hernadi, Ferenc; Eke, Katalin; Petrikovics, Ilona
PA Chinoin Gyogyszer es Vegyeszeti Termekek Gyara R. T., Hung.
SO Ger. (East), 38 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 203053	A5	19831012	DD 1982-240119	19820524
			DD 1982-240119	19820524

AB Carbamoyl, thiocarbamoyl, and selenocarbamoyl derivs. of aminoacetamidocephems and aminoacetamidopenams were prepared Thus, cephalexin was treated with PhNCS to give I which had min. inhibitory concentrate against Bacillus cereus β-lactamase of < 0.32 μM.
IT **84381-39-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and β-lactamase-inhibiting activity of)
RN 84381-39-5 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-[[phenyl[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]acetyl]amino]-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-38-4
CMF C24 H21 F3 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



IT **84380-85-8P 84381-37-3P 84381-41-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 84380-85-8 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-7-[[[[(1-naphthalenylamino)thioxomethyl]amino]phenylacetyl]amino]-8-oxo-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84380-84-7
CMF C27 H24 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 84381-37-3 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-[[phenyl[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]acetyl]amino]-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-36-2
CMF C24 H21 F3 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 84381-41-9 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-7-[[[[[(3-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino]-8-oxo-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-40-8
CMF C23 H21 N5 O6 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1983:71804 CAPLUS
DN 98:71804
TI β-Lactam derivatives and pharmaceutical compositions containing them
PA Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt. , Hung.
SO Belg., 39 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	BE 893057	A1	19820830	BE 1982-207990		19820503
				HU 1981-1154	A	19810504
	HU 33811	O	19841228	HU 1981-1154		19810504
	SE 8202674	A	19821105	SE 1982-2674		19820428
				HU 1981-1154	A	19810504
	DE 3215941	A1	19830505	DE 1982-3215941		19820429
				HU 1981-1154	A	19810504
	DK 8201982	A	19821105	DK 1982-1982		19820503
				HU 1981-1154	A	19810504
	FI 8201551	A	19821105	FI 1982-1551		19820503
				HU 1981-1154	A	19810504
	NO 8201456	A	19821105	NO 1982-1456		19820503
				HU 1981-1154	A	19810504
	AU 8283212	A1	19821111	AU 1982-83212		19820503
				HU 1981-1154	A	19810504
	NL 8201810	A	19821201	NL 1982-1810		19820503
				HU 1981-1154	A	19810504
	FR 2509311	A1	19830114	FR 1982-7659		19820503
				HU 1981-1154	A	19810504
	ES 511884	A1	19830816	ES 1982-511884		19820503
				HU 1981-1154	A	19810504
	GB 2101586	A	19830119	GB 1982-12825		19820504
				HU 1981-1154	A	19810504
	JP 58013590	A2	19830126	JP 1982-73490		19820504
				HU 1981-1154	A	19810504

AB β-Lactams I [X = O, S, Se; R = substituted amino, substituted hydrazino; R1-R4 = H, alkyl, (un)substituted Ph; R5 = Me, CH2OAc, heterocyclylthiomethyl; n = 0, 1], their S-oxides and dioxides and penicillin analogs (61 compds.) were prepared Thus cephalexin was treated with 4-MeC6H4NCS to give I (X = S, R = 4-MeC6H4NH, R1 = R3 = H, R4 = Ph, R5 = Me, n = 0) as its NEt3 salt which gave 50% inhibition of Escherichia coli β-lactamase at 43.19 μmol.
IT **84381-39-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and β-lactamase inhibiting activity of)
RN 84381-39-5 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-[[phenyl[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]acetyl]amino]-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-38-4
CMF C24 H21 F3 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



IT **84380-85-8P 84381-37-3P 84381-41-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 84380-85-8 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-7-[[[[(1-naphthalenylamino)thioxomethyl]amino]phenylacetyl]amino]-8-oxo-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84380-84-7
CMF C27 H24 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 84381-37-3 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-[[phenyl[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]acetyl]amino]-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-36-2
CMF C24 H21 F3 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 84381-41-9 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-methyl-7-[[[[[(3-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino]-8-oxo-, [6R-[6α,7β(R*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-40-8
CMF C23 H21 N5 O6 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1981:65461 CAPLUS
DN 94:65461
TI 4-Unsubstituted azetidinone derivatives
IN Hashimoto, Masashi; Hemmi, Keiji; Kamiya, Takashi; Komori, Tadaaki; Nakaguti, Osamu; Saito, Yoshihisa; Shiokawa, Youichi; Takasugi, Hisahi; Takaya, Takao; Teraji, Tsutomu
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S., 130 pp. Cont.-in-part of U.S. Ser. No. 694,891, abandoned.
CODEN: USXXAM
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4207234	A	19800610	US 1977-858375	19771207
				US 1975-593668 A2	19750707
				US 1976-694891 A2	19760610
	US 4472300	A	19840918	US 1980-130205	19800313
				US 1975-593668 A2	19750707
				US 1976-694891 A2	19760610
				US 1977-858375 A3	19771207

OS CASREACT 94:65461
AB Lactacillanic acids and analogs I (R = NH2, acylamino, benzenesulfonamido; R1 = CO2H, pharmaceutically acceptable salt or ester derivative of CO2H; R2 = H, NH2, NO2, halo, alkoxy, alkylthio; R3 = H, OH, alkyl, alkylthio, OCH2Ph; R4 = H, Halo, alkoxy, alkylthio), which showed bactericidal activity, were prepared Thus, 3-aminolactacillanic acid reacted with PhCH2COCl in water-Me2CO containing NaHCO3 to yield I (R = PhCH2CONH, R1 = CO2H, R3 = OH, R2 = R4 = H).
IT **59510-75-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(deacylation of)
RN 59510-75-7 CAPLUS
CN 1-Azetidineacetic acid, 3-[[[4-[3-(acetylamino)-3-carboxypropoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



IT **59510-76-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacylation of)
RN 59510-76-8 CAPLUS
CN 1-Azetidineacetic acid, 3-[[[4-[3-carboxy-3-[[(1-naphthalenylamino)thioxomethyl]amino]propoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **59510-75-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59510-75-7 CAPLUS
CN 1-Azetidineacetic acid, 3-[[[4-[3-(acetylamino)-3-carboxypropoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]ami

no]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:181065 CAPLUS
DN 92:181065
TI Studies on heterocyclic compounds. Preparation of N1-(4-arylthiazol-2-ylacetylamino)-N2-aryl and N1-(substituted benzothiazol-2-ylacetylamino)-N2-aryl thioureas
AU Dash, B.; Praharaj, S.; Mohapatra, P. K.
CS Dep. Chem., Utkal Univ., Bhubaneswar, 751 004, India
SO Journal of the Institution of Chemists (India) (1979), 51(4), 151-5
CODEN: JOICA7; ISSN: 0020-3254
DT Journal
LA English
OS CASREACT 92:181065
AB Thioureas I and II (R = H, Me, Cl, OMe; R1 = optionally substituted Ph, 1-naphthyl; R2 = H, 6-Me, 6-Cl, 6-NO2, 6-Ph, 5-NO2, 4-OMe) were obtained by treating the thiazoleamines with ClCH2COCl and R1NHCSNH2. At 500 ppm I and II caused 60.2-88.8% inhibition of Helminthosporium sativum growth.
IT **73458-16-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and fungicidal activity of)
RN 73458-16-9 CAPLUS
CN Acetamide, 2-[[(1-naphthalenylamino)thioxomethyl]amino]-N-(4-phenyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1976:421078 CAPLUS
DN 85:21078
TI Azetidinone derivatives
IN Kamiya, Takashi; Yoshihisa, Takarazuka; Hashimoto, Masashi; Teraji, Tsutomu; Takaya, Takao; Komori, Tadaaki; Nakaguti, Osamu; Oku, Teruo; Shiokawa, Youichi; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Ger. Offen., 318 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DE 2529941	A1	19760408	DE 1975-2529941		19750704
				JP 1974-77091	A	19740704
				JP 1974-85526	A	19740724
				JP 1974-88452	A	19740731
				JP 1975-2650	A	19741223
	JP 51125061	A2	19761101	JP 1974-77091	A	19740704
	JP 51125062	A2	19761101	JP 1974-85526	A	19740724
	JP 51125064	A2	19761101	JP 1974-88452	A	19740731
	JP 51075056	A2	19760629	JP 1975-2650	A	19741223
	BE 830934	A1	19760102	BE 1975-157924		19750702
				JP 1974-77091	A	19740704
	CH 618161	A	19800715	CH 1975-8634		19750702
				JP 1974-77091	A	19740704
	DK 7503023	A	19760105	DK 1975-3023		19750703
				JP 1974-77091	A	19740704

			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-2650	A	19741223
			JP 1975-3779	A	19741225
			JP 1975-1272	A	19741228
			JP 1975-16584	A	19750207
			JP 1975-18241	A	19750212
			JP 1975-30356	A	19750312
			JP 1975-32702	A	19750317
			JP 1975-32703	A	19750317
			JP 1975-33292	A	19750318
			JP 1975-34830	A	19750319
			JP 1975-33821	A	19750320
			JP 1975-33822	A	19750320
FI 7501949	A	19760105	FI 1975-1949		19750703
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-2650	A	19741223
			JP 1975-3779	A	19741225
			JP 1975-1272	A	19741228
			JP 1975-16584	A	19750207
			JP 1975-18241	A	19750212
			JP 1975-30356	A	19750312
			JP 1975-32702	A	19750317
			JP 1975-32703	A	19750317
			JP 1975-33292	A	19750318
			JP 1975-34830	A	19750319
			JP 1975-33821	A	19750320
			JP 1975-33822	A	19750320
NO 7502419	A	19760106	NO 1975-2419		19750703
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-2650	A	19741223
			JP 1975-1272	A	19741228
			JP 1975-16584	A	19750207
			JP 1975-18241	A	19750212
			JP 1974-30356	A	19750312
			JP 1975-32702	A	19750317
			JP 1975-32703	A	19750317
			JP 1975-33292	A	19750318
			JP 1975-34830	A	19750319

			JP 1975-33821	A	19750320
			JP 1975-33822	A	19750320
FR 2278335	A1	19760213	FR 1975-20990		19750703
FR 2278335	B1	19821217			
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1975-2650	A	19741223
SE 428799	B	19830725	SE 1975-7683		19750703
SE 428799	C	19831103			
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-2650	A	19741223
NL 7508008	A	19760106	NL 1975-8008		19750704
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
AU 7582778	A1	19770106	AU 1975-82778		19750704
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-2650	A	19741223
			JP 1975-3779	A	19741225
			JP 1975-1272	A	19741228
			JP 1975-16584	A	19750207
			JP 1975-18241	A	19750212
			JP 1975-30356	A	19750312
			JP 1975-32702	A	19750317
			JP 1975-32703	A	19750317
			JP 1975-33292	A	19750318
			JP 1975-34830	A	19750319
			JP 1975-33821	A	19750320
			JP 1975-33822	A	19750320
ES 439134	A1	19770301	ES 1975-439134		19750704
			JP 1974-77091	A	19740704
ZA 7504306	A	19770525	ZA 1975-4306		19750704
			JP 1974-77091	A	19740704
GB 1519495	A	19780726	GB 1975-28394		19750704
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1975-2650	A	19741223
HU 172476	P	19780928	HU 1975-FU336		19750704
			JP 1974-77091	A	19740704
AT 7505170	A	19790715	AT 1975-5170		19750704
AT 355034	B	19800211			
			JP 1974-77091	A	19740704

CA 1063108	A1	19790925	CA 1975-230828		19750704
			JP 1974-77091	A	19740704
AT 7806099	A	19790915	AT 1978-6099		19780822
			JP 1974-88452	A	19740731
			AT 1975-5170	A	19750704
AT 7806098	A	19800415	AT 1978-6098		19780822
AT 359514	B	19801110			
			JP 1974-85526	A	19740724
			AT 1975-5170	A	19750704
SE 7903460	A	19790419	SE 1979-3460		19790419
			JP 1974-77091	A	19740704
			JP 1974-85526	A	19740724
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
SE 7903504	A	19790420	SE 1979-3504		19790420
			JP 1974-77091	A	19740704
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
CH 637924	A	19830831	CH 1980-5357		19800711
			JP 1974-85526	A	19740724
			CH 1975-8634	A	19750702

PATENT FAMILY INFORMATION:

FAN 1977:139821

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	JP 51110556	A2	19760930	JP 1975-36267	A	19750325
	JP 51029476	A2	19760312	JP 1974-100159	A	19740830
	JP 51029477	A2	19760312	JP 1974-101712	A	19740902
	JP 51029478	A2	19760312	JP 1974-102288	A	19740904
	JP 51125065	A2	19761101	JP 1974-136561	A	19741126
	JP 51125271	A2	19761101	JP 1974-138137	A	19741129
	JP 51075057	A2	19760629	JP 1975-3779	A	19741225
	JP 51125272	A2	19761101	JP 1975-1272	A	19741228
	JP 51091249	A2	19760810	JP 1975-16584	A	19750207
	JP 51095056	A2	19760820	JP 1975-18241	A	19750212
	JP 51105052	A2	19760917	JP 1975-30356	A	19750312
	JP 51108054	A2	19760925	JP 1975-32702	A	19750317
	JP 51108055	A2	19760925	JP 1975-32703	A	19750317
	JP 51122058	A2	19761025	JP 1975-33292	A	19750318

JP 51108059	A2	19760925	JP 1975-34830	A	19750319
JP 51108057	A2	19760925	JP 1975-33821	A	19750320
JP 51108058	A2	19760925	JP 1975-33822	A	19750320
DK 7902705	A	19790626	DK 1979-2705		19790626
			JP 1974-77091	A	19740704
			JP 1974-88452	A	19740731
			JP 1974-100159	A	19740830
			JP 1974-101712	A	19740902
			JP 1974-102288	A	19740904
			JP 1974-136561	A	19741126
			JP 1974-138137	A	19741129
			JP 1975-2650	A	19741223
			JP 1975-3779	A	19741225
			JP 1975-1272	A	19741228
			JP 1975-16584	A	19750207
			JP 1975-18241	A	19750212
			JP 1975-30356	A	19750312
			JP 1975-32702	A	19750317
			JP 1975-32703	A	19750317
			JP 1975-33292	A	19750318
			JP 1975-34830	A	19750319
			JP 1975-33821	A	19750320
			JP 1975-33822	A	19750320
			JP 1975-36267	A	19750325

AB After the antibiotic FR-1923 (obtained from fermentation liquor of Nocardia) was identified as I, 543 analogs [II; R = NH2 or acylamino; R1 = alkyl (saturated or unsatd., straight-chain or branched) with substituents, e.g., CO2H (or its derivs.), CN, OH, NH2, Ph or substituted Ph] were prepared by standard procedures and shown to be effective against, e.g., Bacillus subtilis, Escherichia coli, and Staphylococcus aureus.

IT **59510-75-7P 59510-76-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 59510-75-7 CAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-(acetylamino)-3-carboxypropoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 59510-76-8 CAPLUS
CN 1-Azetidineacetic acid, 3-[[[4-[3-carboxy-3-[[(1-naphthalenylamino)thioxomethyl]amino]propoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=>